BioSpace News Archive

Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today announced that Don Haut, PhD, has been appointed its Chief Business Officer to oversee business development strategy and execution. “

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced that it is providing GIAPREZA™ (angiotensin II) for named patient emergency use in patients with septic shock due to COVID-19 at University Hospital Münster in Germany. GIAPREZA is being made available for named patient emer

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has gone live with an initial phase of its digital pathology solution at New York’s Hospital for Special Surgery (HSS), the world’s leading academic medical center focused on musculoskeletal health.

As the global health crisis quickly spreads in the United States, officials face the daunting task of treating patients in person and monitoring their progress.

Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has entered into a new collaboration agreement with a large pharmaceutical company to advance its ADMET Predictor® machine learning software for use within integrated drug discovery workflows

Calyxt, Inc. (NASDAQ: CLXT), a plant-based technology company, has licensed a new method to help increase plant gene editing efficiency from the University of Minnesota.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the company is launching a blood-based immunoassay kit to identify antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19. Preliminary performance of the assay has been established and the kit is now undergoing clinical evaluation in several hospitals to

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Toro Merger Sub, Inc., a wholly owned subsidiary of Gilead (“Purchaser”), to acquire Forty Seven, Inc. (Nasdaq: FTSV) for $95.50 per share, net to the seller in cash, without interest, or approximately $4.9 billion in the aggregate. On March 2, 2020, Gilead and Forty Seven announced that Forty S

Lattice Biologics Ltd. is pleased to announce that it has entered into a definitive agreement with Alumina Partners Ltd. for a commitment of up to $6,000,000 CDN in an at-will offering facility.

The research study presented in this report provides a comprehensive and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Coronary Stent Market.